NovaBay Pharma (NBY) Misses Q1 EPS by 14c

NovaBay Pharma (NYSE: NBY) reported Q1 EPS of ($0.26), $0.14 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $3.69 million versus the consensus estimate of $3.89 million.

For earnings history and earnings-related data on NovaBay Pharma (NBY) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)